• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全科医疗中慢性肾脏病早期诊断的临床与经济影响:ENDORSE研究

Clinical and Economic Impact of Early Diagnosis of Chronic Kidney Disease in General Practice: The Endorse Study.

作者信息

Pesce Francesco, Bruno Giacomo Matteo, Colombo Giorgio Lorenzo, Di Matteo Sergio, Maurizi Anna Rita, Mongelli Valentina, Mele Silvia, Narici Lavinia, Bianchi Stefano, Bonomini Mario, Castellano Giuseppe, De Nicola Luca, Gambaro Giovanni, Grandaliano Giuseppe, La Manna Gaetano, Pani Antonello, Ranghino Andrea, Gesualdo Loreto

机构信息

Division of Renal Medicine, "Fatebenefratelli Isola Tiberina-Gemelli Isola", Rome, 00186, Italy.

Department of Drug Sciences, University of Pavia, Pavia, Italy.

出版信息

Clinicoecon Outcomes Res. 2024 Aug 5;16:547-555. doi: 10.2147/CEOR.S470728. eCollection 2024.

DOI:10.2147/CEOR.S470728
PMID:39130105
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC11313497/
Abstract

INTRODUCTION

The underdiagnosis of chronic kidney disease (CKD) remains a significant public health concern. The Early chroNic kiDney disease pOint of caRe Screening (ENDORSE) project aimed to evaluate the clinical and economic implications of a targeted training intervention for general practitioners (GPs) to enhance CKD awareness and early diagnosis.

METHODS

Data on estimated Glomerular Filtration Rate (eGFR) and Urinary Albumin-Creatinine Ratio (uACR) were collected by 53 Italian GPs from 112,178 patients at baseline and after six months. The intervention involved six months of hybrid training provided by 11 nephrologists, which included formal lectures, instant messaging support, and joint visits for complex cases.

RESULTS

The results demonstrated a substantial increase in the use of eGFR (+44.7%) and uACR (+95.2%) tests. This led to a 128.9% rise in the number of individuals screened for CKD using the KDIGO classification, resulting in a 62% increase in CKD diagnoses. The intervention's impact was particularly notable in high-risk groups, including patients with type 2 diabetes, hypertension, and heart failure.

DISCUSSION

A budget impact analysis projected cumulative five-year savings of €1.7 million for the study cohort. When these findings were extrapolated to the entire Italian CKD population, potential savings were estimated at €106.6 million, highlighting significant cost savings for the national health service. The clinical simulation assumed that early diagnosed CKD patients would be treated according to current indications for dapagliflozin, which slows disease progression.

CONCLUSION

The ENDORSE model demonstrated that targeted training for GPs can significantly improve early CKD detection, leading to better patient outcomes and considerable economic benefits. This approach shows promise for broader implementation to address the underdiagnosis of CKD on a national and potentially international scale.

摘要

引言

慢性肾脏病(CKD)的诊断不足仍然是一个重大的公共卫生问题。早期慢性肾脏病初级保健筛查(ENDORSE)项目旨在评估针对全科医生(GPs)的定向培训干预措施对提高CKD知晓率和早期诊断的临床及经济影响。

方法

53名意大利全科医生收集了112,178名患者在基线期和六个月后的估计肾小球滤过率(eGFR)和尿白蛋白肌酐比值(uACR)数据。干预措施包括由11名肾病专家提供的为期六个月的混合培训,其中包括正式讲座、即时通讯支持以及针对复杂病例的联合出诊。

结果

结果显示,eGFR检测的使用量大幅增加(+44.7%),uACR检测的使用量增加了95.2%。这使得使用KDIGO分类法筛查CKD的人数增加了128.9%,CKD诊断数量增加了62%。该干预措施在高危人群中影响尤为显著,包括2型糖尿病、高血压和心力衰竭患者。

讨论

预算影响分析预计,该研究队列在五年内累计节省170万欧元。将这些结果外推至整个意大利CKD人群时,预计潜在节省金额为1.066亿欧元,凸显了对国家卫生服务的显著成本节约。临床模拟假设,早期诊断的CKD患者将根据目前达格列净的适应证进行治疗,该药可减缓疾病进展。

结论

ENDORSE模式表明,针对全科医生的定向培训可显著改善CKD的早期检测,带来更好的患者预后和可观的经济效益。这种方法有望在全国乃至国际范围内更广泛地实施,以解决CKD诊断不足的问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11e9/11313497/9ecc9acc3198/CEOR-16-547-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11e9/11313497/9ecc9acc3198/CEOR-16-547-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11e9/11313497/9ecc9acc3198/CEOR-16-547-g0001.jpg

相似文献

1
Clinical and Economic Impact of Early Diagnosis of Chronic Kidney Disease in General Practice: The Endorse Study.全科医疗中慢性肾脏病早期诊断的临床与经济影响:ENDORSE研究
Clinicoecon Outcomes Res. 2024 Aug 5;16:547-555. doi: 10.2147/CEOR.S470728. eCollection 2024.
2
"The Disease Awareness Innovation Network" for chronic kidney disease identification in general practice.“疾病认知创新网络”在全科医学中用于识别慢性肾脏病。
J Nephrol. 2022 Nov;35(8):2057-2065. doi: 10.1007/s40620-022-01353-6. Epub 2022 Jun 14.
3
Estimated health economic impact of conducting urine albumin-to-creatinine ratio testing alongside estimated glomerular filtration rate testing in the early stages of chronic kidney disease in patients with type 2 diabetes.在2型糖尿病患者慢性肾病早期,同时进行尿白蛋白与肌酐比值检测和估计肾小球滤过率检测的估计健康经济影响。
J Med Econ. 2023 Jan-Dec;26(1):935-943. doi: 10.1080/13696998.2023.2235922.
4
Changes in GFR and Albuminuria in Routine Clinical Practice and the Risk of Kidney Disease Progression.在常规临床实践中肾小球滤过率和白蛋白尿的变化与肾脏疾病进展的风险。
Am J Kidney Dis. 2021 Sep;78(3):350-360.e1. doi: 10.1053/j.ajkd.2021.02.335. Epub 2021 Apr 23.
5
Relationship Between Lipoprotein(a), Renal Function Indicators, and Chronic Kidney Disease: Evidence From a Large Prospective Cohort Study.载脂蛋白(a)与肾功能指标及慢性肾脏病的关系:来自一项大型前瞻性队列研究的证据。
JMIR Public Health Surveill. 2024 Jan 31;10:e50415. doi: 10.2196/50415.
6
Identification and outcomes of KDIGO-defined chronic kidney disease in 1.4 million U.S. Veterans with heart failure.在美国 140 万心力衰竭退伍军人中识别和评估 KDIGO 定义的慢性肾脏病及其结局。
Eur J Heart Fail. 2024 May;26(5):1251-1260. doi: 10.1002/ejhf.3210. Epub 2024 May 3.
7
The clinical utility and cost impact of cystatin C measurement in the diagnosis and management of chronic kidney disease: A primary care cohort study.胱抑素C检测在慢性肾脏病诊断和管理中的临床效用及成本影响:一项初级保健队列研究
PLoS Med. 2017 Oct 10;14(10):e1002400. doi: 10.1371/journal.pmed.1002400. eCollection 2017 Oct.
8
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.达格列净对伴有和不伴有 2 型糖尿病的慢性肾脏病患者尿白蛋白排泄的影响:来自 DAPA-CKD 试验的预设分析。
Lancet Diabetes Endocrinol. 2021 Nov;9(11):755-766. doi: 10.1016/S2213-8587(21)00243-6. Epub 2021 Oct 4.
9
Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.早期转介策略在管理有肾脏疾病标志物的人群中的应用:对临床有效性、成本效益和经济分析证据的系统评价。
Health Technol Assess. 2010 Apr;14(21):1-184. doi: 10.3310/hta14210.
10
Detection and awareness of moderate to advanced CKD by primary care practitioners: a cross-sectional study from Italy.初级保健医生对中度至重度慢性肾脏病的检测与认知:一项来自意大利的横断面研究
Am J Kidney Dis. 2008 Sep;52(3):444-53. doi: 10.1053/j.ajkd.2008.03.002. Epub 2008 May 12.

引用本文的文献

1
Optimizing urine albumin-to-creatinine ratio testing and referral pathways for chronic kidney disease: a nominal group technique consensus study among Italian experts.优化慢性肾脏病尿白蛋白与肌酐比值检测及转诊途径:一项意大利专家的名义群体技术共识研究
J Nephrol. 2025 Aug 20. doi: 10.1007/s40620-025-02371-w.
2
Guideline-Recommended Disease-Modifying Therapies for Patients with Cardiorenal Disease: A Call-to-Action Narrative Review.针对心肾疾病患者的指南推荐疾病改善疗法:行动呼吁叙述性综述
Adv Ther. 2025 May 28. doi: 10.1007/s12325-025-03228-1.

本文引用的文献

1
"The Disease Awareness Innovation Network" for chronic kidney disease identification in general practice.“疾病认知创新网络”在全科医学中用于识别慢性肾脏病。
J Nephrol. 2022 Nov;35(8):2057-2065. doi: 10.1007/s40620-022-01353-6. Epub 2022 Jun 14.
2
Epidemiology of chronic kidney disease: an update 2022.慢性肾脏病流行病学:2022年最新情况
Kidney Int Suppl (2011). 2022 Apr;12(1):7-11. doi: 10.1016/j.kisu.2021.11.003. Epub 2022 Mar 18.
3
More on the invisibility of chronic kidney disease… and counting.关于慢性肾病的隐匿性……以及相关数据统计。
Clin Kidney J. 2021 Nov 27;15(3):388-392. doi: 10.1093/ckj/sfab240. eCollection 2022 Mar.
4
15-year-change of phenotype and prognosis in non-dialysis CKD patients referred to a nephrology clinic.非透析慢性肾脏病患者在肾病科就诊时的表型和预后 15 年变化。
Int Urol Nephrol. 2022 Mar;54(3):679-686. doi: 10.1007/s11255-021-02944-1. Epub 2021 Jul 12.
5
Chronic Kidney Disease Progression and Transition Probabilities in a Large Preventive Cohort in Colombia.哥伦比亚一个大型预防队列中的慢性肾脏病进展及转变概率
Int J Nephrol. 2021 Mar 31;2021:8866446. doi: 10.1155/2021/8866446. eCollection 2021.
6
The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.慢性肾脏病早期识别与干预的理由:来自改善全球肾脏病预后组织(KDIGO)争议会议的结论
Kidney Int. 2021 Jan;99(1):34-47. doi: 10.1016/j.kint.2020.10.012. Epub 2020 Oct 27.
7
Direct healthcare costs of chronic kidney disease management in Italy: What cost-savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesis-stimulating agents?意大利慢性肾脏病管理的直接医疗成本:更高的生物类似药使用率和更合理地使用促红细胞生成素能实现哪些成本节约?
Pharmacoepidemiol Drug Saf. 2021 Jan;30(1):65-77. doi: 10.1002/pds.5152. Epub 2020 Nov 16.
8
Dapagliflozin in Patients with Chronic Kidney Disease.达格列净治疗慢性肾脏病患者。
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
9
Prevalence of chronic kidney disease in the Lazio region, Italy: a classification algorithm based on health information systems.意大利拉齐奥地区慢性肾脏病的患病率:基于健康信息系统的分类算法。
BMC Nephrol. 2020 Jan 28;21(1):23. doi: 10.1186/s12882-020-1689-z.
10
A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases.一个用于宣传和沟通的数字——全球超过8.5亿人患有肾脏疾病。
Kidney Int. 2019 Nov;96(5):1048-1050. doi: 10.1016/j.kint.2019.07.012. Epub 2019 Sep 30.